FARMACIA Y TECNOLOGÍA FARMACÉUTICA
Departamento
MIGUEL ÁNGEL
CALLEJA HERNÁNDEZ
Investigador en el periodo 2016-2017
Publicaciones en las que colabora con MIGUEL ÁNGEL CALLEJA HERNÁNDEZ (53)
2024
-
Factors Contributing to Negative Outcomes Associated with Medications and Drug-Related Problems in Kidney Replacement Therapy—A Hospital-Based Prospective Observational Study
Journal of Clinical Medicine, Vol. 13, Núm. 4
2023
-
Medication Review with Follow-Up for End-Stage Renal Disease: Drug-Related Problems and Negative Outcomes Associated with Medication—A Systematic Review
Journal of Clinical Medicine, Vol. 12, Núm. 15
2021
-
Association between polymorphisms in the vitamin D receptor and susceptibility to multiple sclerosis
Pharmacogenetics and Genomics, Vol. 31, Núm. 2, pp. 40-47
-
Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives
Mutation Research - Reviews in Mutation Research, Vol. 788
-
Impact of a risk-sharing agreement in rheumatoid arthritis in Spain
Health Policy, Vol. 125, Núm. 3, pp. 335-340
-
Therapeutic value of single nucleotide polymorphisms on the efficacy of new therapies in patients with multiple sclerosis
Journal of Personalized Medicine, Vol. 11, Núm. 5
2020
-
Effect of genetic polymorphisms on therapeutic response in multiple sclerosis relapsing-remitting patients treated with interferon-beta
Mutation Research - Reviews in Mutation Research, Vol. 785
2019
-
Clinical pharmacy services: From cost-effectiveness analysis to a productivity indicators model
European Journal of Hospital Pharmacy
-
Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients
Pharmacogenomics Journal, Vol. 19, Núm. 2, pp. 164-177
2018
-
Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer
Pathology Research and Practice, Vol. 214, Núm. 1, pp. 44-52
2017
-
Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer
Mutation Research - Reviews in Mutation Research, Vol. 771, pp. 32-58
-
Cytokine single-nucleotide polymorphisms and risk of non-small-cell lung cancer
Pharmacogenetics and Genomics, Vol. 27, Núm. 12, pp. 438-444
-
Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer
Surgical Oncology, Vol. 26, Núm. 3, pp. 278-285
2016
-
Liquid biopsy in early stage lung cancer
Translational Lung Cancer Research, Vol. 5, Núm. 5, pp. 517-524
-
Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients
Pharmacological Research, Vol. 111, pp. 877-884
-
Resultados negativos asociados a la medicación en los pacientes con fibrilación auricular permanente atendidos en un servicio de urgencias hospitalario
Emergencias, Vol. 28, Núm. 2, pp. 75-82
2015
-
Differences in cancer drug assessment between Spain and the United Kingdom
European Journal of Cancer, Vol. 51, Núm. 13, pp. 1843-1852
-
MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer
Pharmacological Research, Vol. 102, pp. 90-106
-
MET: A new promising biomarker in non-small-cell lung carcinoma
Pharmacogenomics, Vol. 16, Núm. 6, pp. 631-647
-
Negative outcomes associated with medication in patients with chronic atrial fibrillation who present at the emergency department
Journal of Clinical Pharmacy and Therapeutics, Vol. 40, Núm. 4, pp. 452-460